Research
Glucomannan
48 peer-reviewed studies curated from PubMed and Semantic Scholar.
Studies
Sorted by quality and recency
The effect of glucomannan supplementation on lipid profile in adults: a GRADE-assessed systematic review and meta-analysis.
This meta-analysis evaluated the impact of glucomannan supplementation on lipid profiles in adults. It found that glucomannan significantly decreased total cholesterol and LDL-C levels, but did not significantly alter triglycerides, Apo A1, APO-B/ A1 ratio, or LDL-C/ HDL-C ratio.
Does glucomannan supplementation exert profitable effects on serum lipid profile in adults? A systematic review and meta-analysis.
Systematic review and meta-analysis examining the effects of glucomannan on serum lipid profile in adults. Glucomannan significantly reduced total cholesterol and LDL-C levels but had no effect on HDL-C and triglycerides. The decreases were not clinically important, suggesting glucomannan as an adjunctive therapy for dyslipidemia.
Effects of Glucomannan Supplementation on Type II Diabetes Mellitus in Humans: A Meta-Analysis.
Meta-analysis of six RCTs with 440 participants evaluating glucomannan supplementation in type II diabetes patients. Glucomannan reduced total cholesterol, LDL levels, fasting blood glucose, 2-hour postprandial blood glucose, fasting insulin, and serum fructosamine levels, indicating it as an effective nutritional intervention for type II diabetes.
A systematic review and meta-analysis of randomized controlled trials of the effect of konjac glucomannan, a viscous soluble fiber, on LDL cholesterol and the new lipid targets non-HDL cholesterol and apolipoprotein B.
This systematic review and meta-analysis assessed the effect of konjac glucomannan (KJM) on LDL cholesterol, non-HDL cholesterol, and apolipoprotein B. The analysis included 12 RCTs with a total of 370 participants. KJM significantly lowered LDL cholesterol and non-HDL cholesterol, but had no impact on apolipoprotein B.
Effect of glucomannan on plasma lipid and glucose concentrations, body weight, and blood pressure: systematic review and meta-analysis.
Systematic review and meta-analysis of 14 studies (n=531) assessing glucomannan's effects on plasma lipids, body weight, fasting blood glucose, and blood pressure. Glucomannan significantly lowered total cholesterol, LDL cholesterol, triglycerides, body weight, and fasting blood glucose, but did not significantly affect HDL cholesterol or blood pressure.
Dietary fiber supplementation mitigates gestational diabetes risk and preterm birth via gut microbiota modulation: a randomized controlled trial.
RCT with 98 pregnant women at high risk for gestational diabetes, testing soluble dietary fiber supplementation. The fiber group showed improved glycemic control, reduced gestational weight gain, and no preterm births. Microbiome analysis indicated beneficial changes and downregulation of inflammation-related pathways.
Changes of gut microbiota, hormone and glycolipid metabolism by dietary fiber (oat bran) supplementation in patients with laparoscopic sleeve gastrectomy and Roux-en-Y gastric bypass: A randomized controlled study.
RCT of 63 post-bariatric surgery patients comparing standard care to standard care plus 30 g/day oat bran supplementation for 12 weeks. The intervention group showed improved gut microbiota, increased secretion of GLP-1 and PYY, and better metabolic parameters.
Effects of konjac glucomannan on gastrointestinal symptoms and gut microbiota in athletes with functional constipation: a double-blind randomized controlled trial.
Double-blind randomized controlled trial assessing the effects of an 8-week konjac glucomannan intervention on gastrointestinal symptoms and gut microbiota in elite male Taekwondo athletes with functional constipation. The KGM group showed significant improvements in constipation symptoms and gut microbiota diversity compared to placebo.
The Impact of Glucomannan, Inulin, and Psyllium Supplementation (SolowaysTM) on Weight Loss in Adults with FTO, LEP, LEPR, and MC4R Polymorphisms: A Randomized, Double-Blind, Placebo-Controlled Trial
RCT of 112 adults with obesity and specific genetic polymorphisms, testing a fiber supplement (glucomannan, inulin, psyllium) versus placebo for 180 days. The supplement group showed significant reductions in body weight, BMI, fat mass, and visceral fat rating compared to placebo. High incidence of gastrointestinal events was reported in the experimental group.
Effectiveness of a Food Supplement Based on Glucomannan, D-Chiro-Inositol,Blume and Inulin in Patients with Metabolic Syndrome.
RCT of 58 subjects with MetS and T2DM or impaired glucose tolerance taking a supplement of glucomannan, D-chiro-inositol, blume, and inulin for four months. Significant reductions in body weight, BMI, serum insulin, HOMA index, and improvements in cholesterol, triglycerides, and LDL were observed.
Effect of glucomannan on functional constipation in children: a systematic review and meta-analysis of randomised controlled trials.
Systematic review and meta-analysis of RCTs assessing glucomannan's effects on constipation in children. Glucomannan increased defecation frequency but showed no significant effect on stool consistency or treatment success rate. Results are limited by small sample size.
The effect of glucomannan on body weight in overweight or obese children and adults: a systematic review of randomized controlled trials.
Systematic review of RCTs evaluating glucomannan's effect on body weight and BMI in overweight or obese children and adults. Some evidence suggests glucomannan may reduce body weight in adults in the short term, but not BMI. Data in children are too limited for conclusions.
The efficacy of glucomannan supplementation in overweight and obesity: a systematic review and meta-analysis of randomized clinical trials.
Systematic review and meta-analysis of 9 RCTs evaluating glucomannan supplementation for weight loss in overweight and obese participants. The meta-analysis found no statistically significant difference in weight loss between glucomannan and placebo. Adverse events included abdominal discomfort, diarrhea, and constipation.
Effect of two doses of a mixture of soluble fibres on body weight and metabolic variables in overweight or obese patients: a randomised trial.
RCT of 200 overweight or obese patients comparing mixed fibre doses (3 g Plantago ovata husk and 1 g glucomannan) to placebo over 16 weeks. Fibre supplementation increased satiety and significantly reduced LDL-cholesterol levels, but had no significant effect on weight loss, glucose, insulin concentrations, or inflammation markers.
Rifaximin improves symptoms of acquired uncomplicated diverticular disease of the colon.
RCT comparing glucomannan + rifaximin to glucomannan alone in 968 patients with uncomplicated diverticular disease. The glucomannan + rifaximin group showed fewer symptoms and a lower rate of complications compared to glucomannan alone after 12 months.
Highlights of three metabolites HDL and reduction in blood pressure values after dietary fiber supplementation in overweight and obese normotensive women: a metabolomic study.
Randomized double-blind placebo-controlled study assessing the metabolite profile after intervention with mixed dietary fiber in overweight and obese normotensive women. The study found significant differences in HDL metabolites and a reduction in systolic blood pressure by 7 mmHg in the fiber group compared to 4 mmHg in the placebo group.
Konjac Glucomannan Attenuated Triglyceride Metabolism during Rice Gruel Tolerance Test.
RCT with 13 Japanese men investigating the effects of konjac glucomannan (KGM) on triglyceride metabolism during a rice gruel tolerance test. KGM supplementation led to significant reductions in circulating free fatty acids and triglycerides, with increased levels of lipoprotein lipase and GPIHBP1 in the 0.8% KGM group.
Glucomannan Inhibits Rice Gruel-Induced Increases in Plasma Glucose and Insulin Levels.
RCT investigating the effects of glucomannan on pre- and postprandial glucose and insulin levels in 25 Japanese males. Glucomannan dose-dependently inhibited rice gruel-induced increases in 30-min postprandial plasma glucose and insulin levels, with greater effects observed in subjects with borderline glucose tolerance.
No Effect of Glucomannan on Body Weight Reduction in Children and Adolescents with Overweight and Obesity: A Randomized Controlled Trial.
RCT of 96 children with overweight or obesity assessing glucomannan supplementation versus placebo for 12 weeks. Glucomannan had no effect on BMI-for-age z score but resulted in lower cholesterol concentrations and higher blood pressure compared to placebo.
Effect of glucomannan supplementation on body weight in overweight and obese children: protocol of a randomised controlled trial.
This is a protocol for a randomized controlled trial evaluating the efficacy of glucomannan supplementation on body weight in overweight and obese children. The trial will compare glucomannan to placebo over 3 months, with a primary outcome of body mass index-for-age z-score difference.
Low dose chromium-polynicotinate or policosanol is effective in hypercholesterolemic children only in combination with glucomannan.
A double-blind trial in 120 hypercholesterolemic children tested the effects of low-dose chromium-polynicotinate or policosanol combined with glucomannan. The combination reduced total and LDL cholesterol without affecting HDL, triglycerides, or fasting blood glucose. The most significant changes were observed with the glucomannan and chromium-polynicotinate combination.
Glucomannan for abdominal pain-related functional gastrointestinal disorders in children: a randomized trial.
Double-blind, placebo-controlled RCT assessing glucomannan for abdominal pain-related functional gastrointestinal disorders in children. The study found no significant difference between glucomannan and placebo in achieving therapeutic success or improving secondary outcomes.
Safety and efficacy of glucomannan for weight loss in overweight and moderately obese adults.
RCT evaluating glucomannan for weight loss in 53 overweight and moderately obese adults over 8 weeks. No significant difference in weight loss or other efficacy outcomes between glucomannan and placebo groups. Glucomannan was well tolerated.
A modified glucomannan mycotoxin-adsorbing agent counteracts the reduced weight gain and diminishes cecal colonization of Salmonella Typhimurium in T-2 toxin exposed pigs.
RCT investigating the effect of a modified glucomannan binder on Salmonella Typhimurium infection in pigs. The binder counteracted reduced weight gain caused by T-2 toxin and reduced Salmonella colonization in the cecum.
Glucomannan is not effective for the treatment of functional constipation in children: a double-blind, placebo-controlled, randomized trial.
Double-blind, placebo-controlled RCT assessing glucomannan (GNN) for functional constipation in children aged 3-16 years. The study found no significant difference in treatment success between the GNN and placebo groups, with similar stool frequency and consistency outcomes.
Ameliorative effects of konjac glucomannan on human faecal β-glucuronidase activity, secondary bile acid levels and faecal water toxicity towards Caco-2 cells.
Double-blind, placebo- and diet-controlled study assessing the effects of konjac glucomannan supplementation on precancerous markers of colon cancer. KGM supplementation significantly decreased faecal β-glucuronidase activity and secondary bile acid levels, increased faecal bifidobacteria and lactobacilli levels, and reduced DNA damage in Caco-2 cells.
Immediate and long-term effects of glucomannan on total ghrelin and leptin in type 2 diabetes mellitus.
The study investigated the effects of glucomannan as a supplementary treatment in type 2 diabetes mellitus by measuring ghrelin, leptin, and insulin responses to OGTT. Glucomannan enhanced prandial ghrelin reduction when given before glucose load and impeded the rise of fasting ghrelin after 4-week supplementation.
Experiences with three different fiber supplements in weight reduction.
RCT comparing the effects of fiber supplements (glucomannan, guar gum, and alginate) on weight reduction in 176 overweight subjects. All fiber supplements with a 1200 kcal diet induced significant weight reduction compared to placebo, with no significant differences between the fibers. Glucomannan was effective in reducing body weight.
Efficacy of rifaximin on symptoms of uncomplicated diverticular disease of the colon. A pilot multicentre open trial. Diverticular Disease Study Group.
Multicenter open trial of 217 patients with symptomatic uncomplicated diverticular disease treated with glucomannan or glucomannan plus rifaximin. After 12 months, the glucomannan plus rifaximin group showed a 63.9% reduction in clinical score compared to 47.6% in the glucomannan only group, suggesting an advantage of cyclic rifaximin administration.
A Preparatory Study for a Randomized Controlled Trial of Dietary Fiber Intake During Adult Pelvic Radiotherapy
Preparatory study for a randomized controlled trial evaluating dietary fiber intake during pelvic radiotherapy in Swedish gynecological cancer patients. The study assessed feasibility, compliance, participation rate, and logistics, finding that using capsules improved participation rates and allowed for better documentation of intake.
Could dyslipidemic children benefit from glucomannan intake?
A double-blind, randomized, placebo-controlled, cross-over trial in 36 children with primary hypercholesterolemia evaluated the efficacy of glucomannan. The supplement significantly reduced total cholesterol and LDL cholesterol levels, particularly in females, with no major adverse effects.
Supplementation of konjac glucomannan into a low-fiber Chinese diet promoted bowel movement and improved colonic ecology in constipated adults: a placebo-controlled, diet-controlled trial.
This diet-controlled study examined the effects of konjac glucomannan (KGM) supplementation on bowel habits and colonic ecology in 7 constipated subjects. KGM supplementation increased weekly defecation frequency and improved colonic ecology by increasing fecal concentrations of beneficial bacteria and short chain fatty acids.
Glycemic and lipid responses to glucomannan in Thais with type 2 diabetes mellitus.
A single-blind, placebo-controlled, crossover trial in 20 type 2 diabetic patients evaluated glucomannan's effects on glycemic and lipid controls. Glucomannan reduced blood glucose rise and LDL-C levels, and improved HOMA-insulin resistance index and BMI in females. It may benefit glycemic and lipid controls in type 2 diabetes.
Effect of plant sterols and glucomannan on lipids in individuals with and without type II diabetes.
Randomized crossover study of 34 individuals (18 non-diabetic and 16 type II diabetic) assessing the effects of plant sterols and glucomannan on lipid profiles. The combination of glucomannan and plant sterols significantly lowered plasma cholesterol and LDL cholesterol concentrations compared to control.
Fiber (glucomannan) is beneficial in the treatment of childhood constipation.
Double-blind, randomized, crossover study evaluating glucomannan fiber supplementation in 31 children with chronic functional constipation, with or without encopresis. The study found that significantly more children were successfully treated with glucomannan compared to placebo, with fewer complaints of abdominal pain and higher parent ratings of improvement.
Konjac supplement alleviated hypercholesterolemia and hyperglycemia in type 2 diabetic subjects--a randomized double-blind trial.
RCT of konjac glucomannan (KGM) supplement (3.6 g/day) for 28 days in 22 hyperlipidemic type 2 diabetic patients. KGM reduced plasma cholesterol, LDL-cholesterol, total/HDL cholesterol ratio, ApoB, and fasting glucose levels. Fecal neutral sterol and bile acid concentrations increased, suggesting improved blood lipid levels and glucose control.
Beneficial effects of viscous dietary fiber from Konjac-mannan in subjects with the insulin resistance syndrome: results of a controlled metabolic trial.
Controlled metabolic trial investigating the effect of Konjac-mannan (KJM) fiber supplementation on metabolic control in subjects with insulin resistance syndrome. KJM treatment resulted in significant decreases in serum cholesterol, apolipoprotein B, and serum fructosamine, suggesting improved glycemic control and lipid profile.
Long-term blood cholesterol-lowering effects of a dietary fiber supplement.
RCT evaluating the cholesterol-lowering effects of a dietary fiber supplement in subjects with mild to moderate hypercholesterolemia. The fiber group showed significant reductions in LDL cholesterol, total cholesterol, and LDL-C/HDL-C ratio over 51 weeks, without affecting HDL cholesterol or triglycerides.
Effect of short-term ingestion of konjac glucomannan on serum cholesterol in healthy men.
Double-blind crossover, placebo-controlled study of 63 healthy men investigating the effects of konjac glucomannan on serum cholesterol. GM reduced total cholesterol by 10%, LDL-C by 7.2%, triglycerides by 23%, and systolic blood pressure by 2.5%. No significant changes in HDL-C, LDL-C to HDL-C ratio, diastolic blood pressure, or body weight were observed.
Childhood obesity treatment: double blinded trial on dietary fibres (glucomannan) versus placebo.
Double-blinded RCT evaluating glucomannan for childhood obesity management in 60 children. Both glucomannan and placebo groups showed significant decreases in overweight, but no significant difference between groups. Significant differences in lipid metabolism were observed with glucomannan treatment.
[The use of highly purified glucomannan-based fibers in childhood obesity].
RCT evaluating the effectiveness of highly purified glucomannan in 23 obese children compared to 30 obese controls. Treated patients showed significant decreases in excess weight and triglycerides, and a decrease in cholesterol levels, with no important side-effects observed.
Relationship between the Peroxidation of Leukocytes Index Ratio and the Improvement of Postprandial Metabolic Stress by a Functional Food.
A randomized, placebo-controlled, crossover study with 10 healthy subjects investigated the effects of a functional food (Snello cookie) containing glucomannan, inulin, fructooligosaccharides, and Bacillus coagulans on postprandial metabolic stress. The Snello cookie improved postprandial metabolic markers such as insulin, glucose, and triglycerides, and reduced uric acid levels. It also improved the Peroxidation of Leukocytes Index Ratio (PLIR) of lymphocytes.
Konjac-mannan (glucomannan) improves glycemia and other associated risk factors for coronary heart disease in type 2 diabetes. A randomized controlled metabolic trial.
RCT of 11 hyperlipidemic and hypertensive type 2 diabetic patients comparing glucomannan-enriched biscuits to placebo. Glucomannan significantly reduced serum fructosamine, total:HDL cholesterol ratio, and systolic blood pressure, suggesting improved metabolic control.
Efficacy of rifaximin in the treatment of symptomatic diverticular disease of the colon. A multicentre double-blind placebo-controlled trial.
RCT comparing glucomannan plus rifaximin to glucomannan plus placebo in 168 outpatients with symptomatic uncomplicated diverticular disease. After 12 months, 68.9% of the rifaximin group were symptom-free or mildly symptomatic compared to 39.5% in the placebo group.
[Evaluation of the action of glucomannan on metabolic parameters and on the sensation of satiation in overweight and obese patients].
RCT of 30 overweight and obese patients comparing a low-calorie diet plus glucomannan to a low-calorie diet plus placebo for 60 days. The glucomannan group showed more effective results in body weight, blood glucose, total serum cholesterol, and hunger and satiety sensation.
Effect of glucomannan on obese patients: a clinical study.
An eight-week double-blind trial tested glucomannan fiber as a food supplement in 20 obese subjects. Glucomannan led to significant mean weight loss and reductions in serum cholesterol and low-density lipoprotein cholesterol, with no adverse reactions reported.
Safety and efficacy of the nonsystemic chewable complex carbohydrate dietary supplement PAZ320 on postprandial glycemia when added to oral agents or insulin in patients with type 2 diabetes mellitus.
Open-label, sequential dose-escalation study evaluating the efficacy and safety of the dietary supplement PAZ320 in 24 subjects with type 2 diabetes. PAZ320, derived from glucomannan, reduced postprandial glucose excursion in 45% of subjects, with a 40% decrease in gAUC at high doses. No severe hypoglycemia was observed, and gastrointestinal side effects were mild.
Influence of Plantago ovata husk (dietary fiber) on the bioavailability and other pharmacokinetic parameters of metformin in diabetic rabbits
Animal study investigating the influence of Plantago ovata husk on the pharmacokinetics of metformin in diabetic rabbits. The study found that Plantago ovata husk increased the oral bioavailability of metformin by 34.42% when included in the diet and delayed its absorption when administered simultaneously.